Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of MP0317 monotherapy in relapsed or refractory advanced solid tumors
NL-OMON51895Phase 1Active, not recruiting
- Sponsor
- Molecular Partners AG
- Start
- Jan 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MP0317 in Nonhematologic neoplasms, colorectal cancer (CRC), ovarian cancer and 14 more, sponsored by Molecular Partners AG. Primary endpoints: Incidence of dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
MP0317
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)ovarian cancerendometrial cancer (EC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON51895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51895.